Follistatin 344

Follistatin 344 (FS344) is a gene therapy agent that functions as a myostatin and activin inhibitor, with clinical applications primarily focused on neuromuscular disorders.¹,² In patients with Becker muscular dystrophy, intramuscular delivery of the follistatin gene via AAV1 vector demonstrated increased muscle strength and improved ambulation without serious adverse events, with histological evidence showing reduced endomysial connective tissue characteristic of the disease.²,³ The therapeutic mechanism involves blocking myostatin, a protein that limits muscle development, and activin, which plays a role in inflammatory processes; this dual inhibition enables improvements in lean body mass and muscle function.¹,² Early clinical outcomes at 3 months of treatment have shown approximately 2 pounds of lean mass increase and 0.81% reduction in body fat, along with a reported 12-year reduction in epigenetic age in older patients.¹ While preclinical and limited human data support potential applications in degenerative muscle disorders and age-related muscle wasting (sarcopenia), all current formulations remain investigational and are not FDA-approved; further clinical research is necessary to establish efficacy and safety profiles in broader patient populations.³,⁴

Follistatin 344 administration has been associated with injection site pain, redness, or swelling, as well as muscle soreness or swelling post-exercise.⁵,⁶,⁷ Reports from clinical trials and patient data indicate modest increases in LDL cholesterol (approximately 8 mg/dL) in about one-third of recipients, which is typically manageable through diet and lifestyle changes.¹,⁷ Potential risks include weakened tendons and ligaments due to rapid muscle growth outpacing connective tissue adaptation, joint stress, and possible cardiovascular effects such as cardiac hypertrophy.⁵,⁶,⁷,⁸,⁹ Decreased follicle-stimulating hormone secretion, flu-like symptoms with certain formulations, and rare cases of visual impairment at high doses have also been noted.⁵ Theoretical concerns involve promotion of tumorigenesis in cancers like esophagus, skin, and prostate, higher organ rejection risk in transplant patients, and unknown long-term effects including hormonal imbalances or organ stress, given the limited clinical data.⁵,⁶,⁸,⁹ Safety considerations emphasize its lack of approval for therapeutic use, WADA ban since 2019, product contamination risks in unregulated sources, and contraindication in pregnancy.¹,⁴,⁵

Follistatin-344 works by inhibiting myostatin, a protein that naturally suppresses muscle cell growth.¹⁰ Once administered, Follistatin-344 is converted in the body into Follistatin-315, a circulating form capable of systemic myostatin inhibition.¹⁰ This inhibition prevents myostatin from interacting with its receptor (ActRIIB), thereby releasing muscle tissue from its natural growth constraints and enabling increased protein synthesis, satellite cell activation, and muscle fiber differentiation.¹⁰ The peptide also binds to and neutralizes activin, a member of the transforming growth factor-β superfamily involved in inflammatory signaling, contributing to its broader effects on muscle development and metabolic regulation.¹¹ This dual mechanism of myostatin and activin inhibition distinguishes Follistatin-344 from other myostatin-targeting approaches and is associated with increases in both muscle fiber size (hypertrophy) and potential increases in muscle fiber number (hyperplasia) in preclinical models.¹²